{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:09:59Z","timestamp":1791518999149,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology , Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.seizure.2019.02.011","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T23:40:15Z","timestamp":1550792415000},"page":"99-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Association of cutaneous adverse drug reactions due to antiepileptic drugs with HLA alleles in a North Indian population"],"prefix":"10.1016","volume":"66","author":[{"given":"Kavish","family":"Ihtisham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhargavi","family":"Ramanujam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narinder Kumar","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurvinder","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neena","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavna","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavan","family":"Samudrala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1319-7012","authenticated-orcid":false,"given":"Manjari","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.seizure.2019.02.011_bib0005","first-page":"95","article-title":"Cutaneous adverse drug reactions: clinical patterns and causative agents- a 6 years series from Chandigarh, India","volume":"47","author":"Sharma","year":"2001","journal-title":"J Postgrad Med"},{"issue":"November","key":"10.1016\/j.seizure.2019.02.011_bib0010","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the US food and drug administration adverse event reporting system","author":"Borelli","year":"2018","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2019.02.011_bib0015","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/archderm.1991.01680050075007","article-title":"A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures","volume":"127","author":"Strom","year":"1991","journal-title":"Arch Dermatol"},{"issue":"8","key":"10.1016\/j.seizure.2019.02.011_bib0020","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/archderm.1990.01670320127028","article-title":"Incidence of toxic epidermal necrolysis in Italy","volume":"126","author":"Naldi","year":"1990","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.seizure.2019.02.011_bib0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archderm.1990.01670250043005","article-title":"Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985","volume":"126","author":"Roujeau","year":"1990","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.seizure.2019.02.011_bib0030","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1001\/archderm.1991.01680050083008","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany","volume":"127","author":"Sch\u00f6pf","year":"1991","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.seizure.2019.02.011_bib0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archderm.1990.01670250049006","article-title":"The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients","volume":"126","author":"Chan","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.seizure.2019.02.011_bib0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syn- drome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"6982","key":"10.1016\/j.seizure.2019.02.011_bib0045","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.seizure.2019.02.011_bib0050","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*31:01 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2019.02.011_bib0055","series-title":"Medical genetics summaries [internet]","article-title":"Carbamezepine therapy and HLA genotype. 2015 oct 14 [updated 2018 aug 1]","author":"Dean","year":"2019"},{"issue":"4","key":"10.1016\/j.seizure.2019.02.011_bib0060","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4103\/aian.AIAN_234_17","article-title":"Cutaneous adverse drug reactions to lamotrigine and human leukocyte antigen typing in North Indian patients: a case series","volume":"20","author":"Srivastava","year":"2017","journal-title":"Ann Indian Acad Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2019.02.011_bib0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.14581\/jer.16016","article-title":"Spectrum of cutaneous adverse reactions to levetiracetam and human leukocyte antigen typing in North-Indian patients","volume":"6","author":"Ramanujam","year":"2016","journal-title":"J. Epilepsy Res"},{"issue":"7","key":"10.1016\/j.seizure.2019.02.011_bib0070","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/j.1528-1167.2009.02096.x","article-title":"Letter: HLA B*15:02 allele association with oxcarbamazepine-induced skin reactions in epilepsy patient from India","volume":"50","author":"Shankarkumar","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2019.02.011_bib0075","unstructured":"The RegiSCAR project, http:\/\/www.regiscar.org (Accessed 18 September 2018)."},{"key":"10.1016\/j.seizure.2019.02.011_bib0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.0105-4538.2001.00001.x-i8","article-title":"General considerations for skin test procedures in the diagnosis of drug hypersensitivity","volume":"57","author":"Brockow","year":"2002","journal-title":"Allergy"},{"key":"10.1016\/j.seizure.2019.02.011_bib0085","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1034\/j.1600-0536.2001.450601.x","article-title":"European society of contat dermatitis. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions","volume":"45","author":"Barbaud","year":"2001","journal-title":"Contact Dermatitis"},{"issue":"2","key":"10.1016\/j.seizure.2019.02.011_bib0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.cr.7290272","article-title":"A powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci","volume":"15","author":"Shi","year":"2005","journal-title":"Cell Res"},{"key":"10.1016\/j.seizure.2019.02.011_bib0095","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-018-02618-5","article-title":"HLA-B*5701 and HLA-B*5801 in an Indian patient with anti-epileptics induced cutaneous adverse drug reactions","author":"Manoharan","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.seizure.2019.02.011_bib0100","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1528-1167.2009.02138_1.x","volume":"50","author":"Locharernkul","year":"2009","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2019.02.011_bib0105","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/clpt.2012.189","article-title":"HLA genotype and carbamazepine induced cutaneous adverse reactions: a systemic review","volume":"92","author":"Yip","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.seizure.2019.02.011_bib0110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eplepsyres.2015.09.011","article-title":"Do HLA-a markers predict skin-reactions from aromatic antiepileptic drugs in a Norwegian population? A case control study","volume":"118","author":"Shirzadi","year":"2015","journal-title":"Epilepsy Res"},{"issue":"23","key":"10.1016\/j.seizure.2019.02.011_bib0115","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1212\/WNL.0000000000004008","article-title":"HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions","volume":"88","author":"Shi","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.seizure.2019.02.011_bib0120","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.neurol.2017.11.006","article-title":"The HLA-B*15:02 polymorphism and tegretol\u00ae-induced serious cutaneous reactions in epilepsy: an updated systematic review and meta-analysis","volume":"174","author":"Chouchi","year":"2018","journal-title":"Rev Neurol (Paris)"},{"issue":"11","key":"10.1016\/j.seizure.2019.02.011_bib0125","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.humimm.2014.09.022","article-title":"HLA-B\u221715:02 is associated with carbamazepine induced Stevens-Johnson syndrome in North Indian population","volume":"75","author":"Aggarwal","year":"2014","journal-title":"Hum Immunol"},{"key":"10.1016\/j.seizure.2019.02.011_bib0130","series-title":"HLA frequency","first-page":"327","author":"Geer","year":"1998"},{"key":"10.1016\/j.seizure.2019.02.011_bib0135","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1101\/gr.173301","article-title":"Genetic evidence on the origins of Indian caste populations","volume":"11","author":"Bamshad","year":"2001","journal-title":"Genome Res"},{"issue":"3","key":"10.1016\/j.seizure.2019.02.011_bib0140","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/tpj.2013.40","article-title":"HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis","volume":"14","author":"Genin","year":"2014","journal-title":"Pharmacogenom J"},{"issue":"7","key":"10.1016\/j.seizure.2019.02.011_bib0145","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1346-8138.2011.01457.x","article-title":"HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population","volume":"39","author":"Nihara","year":"2012","journal-title":"J Dermatol"},{"issue":"1\u20132","key":"10.1016\/j.seizure.2019.02.011_bib0150","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.eplepsyres.2011.08.010","article-title":"Adverse Drug Reaction Research Group in Korea. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans","volume":"297","author":"Kim","year":"2011","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2019.02.011_bib0155","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/clpt.2013.55","article-title":"HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children","volume":"94","author":"Amstutz","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.seizure.2019.02.011_bib0160","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/epi.12564","article-title":"CPNDS clinical recommendation group. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions","volume":"55","author":"Amstutz","year":"2014","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.seizure.2019.02.011_bib0165","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.seizure.2019.02.011_bib0170","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.alit.2016.06.001","article-title":"A review of toxic epidermal necrolysis management in Japan","volume":"66","author":"Kinoshita","year":"2017","journal-title":"Allergol Int"},{"issue":"7","key":"10.1016\/j.seizure.2019.02.011_bib0175","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/epi.12217","article-title":"HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese","volume":"54","author":"Cheung","year":"2013","journal-title":"Epilepsia"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131118307234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131118307234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:53:04Z","timestamp":1761011584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131118307234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":35,"alternative-id":["S1059131118307234"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2019.02.011","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of cutaneous adverse drug reactions due to antiepileptic drugs with HLA alleles in a North Indian population","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2019.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}